How protein-based COVID vaccines could change the pandemic

Jabs from Novavax and other biotech firms are coming. Scientists say they have a lot to offer.
By
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed  Google Scholar

Access through your institution
Buy or subscribe

Pamela Sherry is eager to become immunized against COVID-19. But she has put off getting a jab.

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 599, 359-360 (2021)

doi: https://doi.org/10.1038/d41586-021-03025-0

Updates & Corrections

  • Clarification 11 November 2021: This story was updated to acknowledge protein-based COVID-19 vaccines already in circulation in countries such as Cuba and Taiwan.

References

  1. Dunkle, L. M. et al. Preprint at medRxiv https://doi.org/10.1101/2021.10.05.21264567 (2021).

  2. Keech, C. et al. N. Engl. J. Med. 383, 2320-2332 (2020).

    Article  PubMed  Google Scholar 

  3. Richmond, P. et al. Lancet https://doi.org/10.1016/S0140-6736(21)00241-5 (2021).

    Article  Google Scholar 

  4. Hsieh, S.-M. et al. Lancet Resp. Med. https://doi.org/10.1016/S2213-2600(21)00402-1 (2021).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing